|Bid||62.21 x 12100|
|Ask||63.42 x 11900|
|Day's Range||62.64 - 63.41|
|52 Week Range||57.28 - 106.80|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam CEO John Maraganore, discusses his company's share price decline and the very high price of his company's drug Onpattro.
It's been nearly seven years since the FDA refused to approve tafamidis's first new drug application, and the field is a lot more crowded now.
Dow Jones component Pfizer gained approval Monday for a drug that treats a rare heart disease — potentially rivaling new drugs from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.73. Losses, adjusted for stock option expense, were $1.42 per share. The results topped Wall Street expectations. ...
In a biotech tie-up, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration agreement Monday with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Regeneron and Alnylam said they will exclusively collaborate on discovering, developing and commercializing new RNA interface — or RNAi — therapeutics for a broad range of disease targets expressed in the eye and central nervous system. The companies will also work on therapies for a select number of targets expressed in the liver. The agreement has Regeneron paying $400 million upfront to Alnylam and buying up to $400 million worth of Alnylam stock at $90 per share.
Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology. Alnylam, which last year won U.S. approval for the first treatment using the Nobel prize-winning technology, has a host of other such therapies in its pipeline for various genetic, cardio-metabolic, liver and eye and central nervous system (CNS) diseases. Regeneron will make a $400 million upfront payment to Alnylam and also purchase 4.44 million of Alnylam common shares at $90 per share.
Alnylam Pharmaceuticals stock slipped Wednesday as investors questioned the safety of its rare-disease drug, dubbed givosiran, in a late-stage test of patients with acute hepatic porphyria.
Alnylam Pharmaceuticals Inc's late-stage trial data on its new gene silencing drug cast doubt on its safety, even as results revealed its effectiveness in treating a rare, painful disease. Alnylam said the drug, givosiran, met the main goal of reducing the yearly number of attacks in patients with acute intermittent porphyria (AIP) - a disease that affects the liver and causes debilitating attacks that render most disabled. Givosiran's efficacy profile looks robust but its safety profile is materially worse than expected, SVB Leerink analyst Mani Foroohar said in a note.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. Warning! GuruFocus has detected 3 Warning Signs with ALNY. For the last quarter Alnylam Pharmaceuticals Inc reported a revenue of $21.0 million, compared with the revenue of $37.92 million during the same period a year ago.
The Cambridge, Massachusetts-based company said it had a loss of $2.09 per share. Losses, adjusted for stock option expense, came to $1.82 per share. The results topped Wall Street expectations. The average ...
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...